We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.57%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.28B
AUM Growth
+$165M
(+15%)
Cap. Flow
+$73.1M
Cap. Flow
% of AUM
5.73%
Top 10 Holdings %
Top 10 Hldgs %
52.86%
Holding
80
New
6
Increased
21
Reduced
22
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
+$24.2M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
+$18.2M |
| 3 |
TELA Bio
TELA
|
+$17.6M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$16.4M |
| 5 |
Outset Medical
OM
|
+$13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLU
BELLUS Health Inc.
BLU
|
+$21.7M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$14.6M |
| 3 |
Krystal Biotech
KRYS
|
+$9.67M |
| 4 |
Keros Therapeutics
KROS
|
+$7.77M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$7.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.83% |
| 2 | Communication Services | 5.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABCM
26
DELISTED
Abcam PLC
ABCM
| $17.4M | 1.36% |
710,745
+331,034
| +87% | +$5.71M |
|
|
27
Keros Therapeutics
KROS
$199M
| $16.7M | 1.31% |
416,830
-177,134
| -30% | -$7.77M |
|
|
AXNX
28
DELISTED
Axonics, Inc. Common Stock
AXNX
| $15.8M | 1.24% |
312,786
+3,546
| +1% | +$189K |
|
|
SCTL
29
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $14.7M | 1.16% |
13,405,030
+4,488,160
| +50% | +$3.95M |
|
30
Tandem Diabetes Care
TNDM
$1.34B
| $14.7M | 1.16% |
600,767
+11,582
| +2% | +$373K |
|
|
31
Outset Medical
OM
$84.7M
| $13.9M | 1.09% |
+42,495
| New | +$13M |
|
32
Insmed
INSM
$21.4B
| $13.6M | 1.07% |
645,686
-105,197
| -14% | -$2M |
|
33
OrthoPediatrics
KIDS
$519M
| $13.1M | 1.03% |
298,976
-2,603
| -0.9% | -$120K |
|
34
Xenon Pharmaceuticals
XENE
$6.06B
| $13M | 1.02% |
338,646
+59,202
| +21% | +$2.35M |
|
|
35
Krystal Biotech
KRYS
$10.1B
| $11.9M | 0.93% |
101,259
-94,721
| -48% | -$9.67M |
|
|
CUTR
36
DELISTED
Cutera, Inc.
CUTR
| $8.64M | 0.68% |
570,729
+861
| +0.2% | +$16.3K |
|
37
MaxCyte
MXCT
$112M
| $8.53M | 0.67% |
1,857,566
+493,344
| +36% | +$2.27M |
|
38
Guardant Health
GH
$21.7B
| $7.08M | 0.55% |
197,704
-7,141
| -3% | -$205K |
|
39
AnaptysBio
ANAB
$1.58B
| $6.55M | 0.51% |
+322,208
| New | +$6.53M |
|
40
Genmab
GMAB
$17.7B
| $6.02M | 0.47% |
158,509
-1,516
| -0.9% | -$60.4K |
|
|
SONX
41
DELISTED
Sonendo, Inc.
SONX
| $5.69M | 0.45% |
4,185,619
| – | – |
|
42
BioMarin Pharmaceuticals
BMRN
$11.6B
| $5.26M | 0.41% |
60,654
-828
| -1% | -$77.9K |
|
43
Pfizer
PFE
$143B
| $5.14M | 0.4% |
140,235
-1,312
| -0.9% | -$51.1K |
|
|
MIRO
44
DELISTED
Miromatrix Medical Inc. Common Stock
MIRO
| $3.9M | 0.31% |
2,225,740
-8,916
| -0.4% | -$11.8K |
|
45
Stevanato
STVN
$5.42B
| $3.7M | 0.29% |
114,276
-1,080
| -0.9% | -$30.3K |
|
46
Bio-Techne
TECH
$11.2B
| $2.71M | 0.21% |
+33,178
| New | +$2.67M |
|
47
Castle Biosciences
CSTL
$855M
| $2.2M | 0.17% |
160,126
-1,492
| -0.9% | -$30.2K |
|
|
OKUR
48
OnKure Therapeutics
OKUR
$154M
| $1.64M | 0.13% |
+25,000
| New | +$2.01M |
|
49
Simulations Plus
SLP
$369M
| $1.53M | 0.12% |
35,355
-348
| -1% | -$15.2K |
|
50
Smith & Nephew
SNN
$13.3B
| $487K | 0.04% |
15,111
| – | – |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, First Light Asset Management held 80 positions worth $1.28B, up 15% from $1.11B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
First Light Asset Management deployed $73.1M of net new capital in Q2 2023, opening 6 new positions and adding to 21 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 757,835 shares worth $21.4M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Communication Services.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $14.6M trimmed.
- First Light Asset Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 757,835 shares worth $21.4M.
- First Light Asset Management added most to Bicycle Therapeutics in Q2 2023, an estimated $24.2M increase.
- First Light Asset Management's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $14.6M.
- First Light Asset Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $21.7M.
- First Light Asset Management's ten largest holdings make up 53% of its $1.28B portfolio in Q2 2023.
- First Light Asset Management opened 6 new positions and closed 1 in Q2 2023.
- First Light Asset Management's portfolio value rose 15% quarter-over-quarter to $1.28B.
Based on First Light Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.